Andrew Aronsohn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11871438/publications.pdf

Version: 2024-02-01

24 papers

762 citations

933447 10 h-index 677142 22 g-index

24 all docs

24 docs citations

times ranked

24

1597 citing authors

#	Article	IF	CITATIONS
1	"Raising HOPE†Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. Transplantation Direct, 2021, 7, e707.	1.6	9
2	Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation, 2021, 105, 1285-1290.	1.0	25
3	You Can't Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2020, 19, 2015-2019.	4.4	1
4	Calciphylaxis in endâ€stage liver and renal disease patients before and after transplant. Clinical Transplantation, 2018, 32, e13272.	1.6	2
5	Pay It Forward: Building Capacity to Treat Hepatitis C by Training Our Own Residents. Hepatology, 2018, 68, 2004-2007.	7.3	4
6	Elimination of Hepatitis B and C Virus Infections. Gastroenterology and Hepatology, 2018, 14, 240-243.	0.1	2
7	Overcoming injustice: A roadmap to improve access to hepatitis C virus therapy for our medicaid patients. Hepatology, 2017, 65, 1735-1740.	7.3	5
8	Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology, 2017, 152, 1090-1099.e1.	1.3	487
9	The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System. Current Hepatology Reports, 2017, 16, 192-197.	0.9	О
10	Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar. PLoS ONE, 2017, 12, e0181603.	2.5	6
11	Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series. Topics in Antiviral Medicine, 2017, 25, 110-113.	0.1	20
12	A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy. ACG Case Reports Journal, 2015, 2, 42-44.	0.4	1
13	Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection. PLoS Pathogens, 2015, 11, e1005325.	4.7	74
14	Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C. Seminars in Liver Disease, 2014, 34, 030-036.	3.6	11
15	Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus. Hepatology, 2014, 59, 1688-1691.	7.3	5
16	Expanding access to hepatitis C virus care: A call to deconstruct individualized therapy. Hepatology, 2014, 59, 13-15.	7.3	13
17	HCV Therapy: Treat now or wait?. Current Hepatitis Reports, 2013, 12, 7-12.	0.3	1
18	Is the HCV Pipeline Heading in the Right Direction?. Gastroenterology, 2013, 144, 482-485.	1.3	4

#	Article	lF	CITATION
19	Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology, 2012, 56, 1591-1592.	7.3	24
20	The long-term horizon: Patients who will remain untreated in the era of triple therapy. Clinical Liver Disease, 2012, 1, 20-23.	2.1	1
21	Hepatobiliary Manifestations of Critically III and Postoperative Patients. Clinics in Liver Disease, 2011, 15, 183-197.	2.1	12
22	HCV Eradication: Implications for Disease Resolution. Current Hepatitis Reports, 2011, 10, 27-32.	0.3	0
23	Distributive justice and the arrival of direct-acting antivirals: Who should be first in line?. Hepatology, 2011, 53, 1789-1791.	7.3	29
24	Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology, 2009, 43, 661-671.	2.2	26